WO2004006923A1 - Derives d'aryl piperidine utilises comme inducteurs d'expression des recepteurs des lipoproteines de basse densite (ldl) permettant de traiter l'hypercholesterolemie - Google Patents

Derives d'aryl piperidine utilises comme inducteurs d'expression des recepteurs des lipoproteines de basse densite (ldl) permettant de traiter l'hypercholesterolemie Download PDF

Info

Publication number
WO2004006923A1
WO2004006923A1 PCT/EP2003/007613 EP0307613W WO2004006923A1 WO 2004006923 A1 WO2004006923 A1 WO 2004006923A1 EP 0307613 W EP0307613 W EP 0307613W WO 2004006923 A1 WO2004006923 A1 WO 2004006923A1
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
piperidin
naphthalen
butyl
group
Prior art date
Application number
PCT/EP2003/007613
Other languages
English (en)
Inventor
Anne Marie Jeanne Bouillot
Bernard Andre Dumaitre
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Priority to AU2003250058A priority Critical patent/AU2003250058A1/en
Publication of WO2004006923A1 publication Critical patent/WO2004006923A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • This invention relates to novel compounds which up-regulate LDL receptor (LDL-r) expression and to processes for their preparation, pharmaceutical compositions 5 containing them and their medical use. More particularly, this invention relates to novel aromatic piperidines and their use in therapy.
  • LDL-r LDL receptor
  • LDL cholesterol is eliminated from plasma by specific binding to LDL-r expressed by the liver. Regulation of LDL-r expression occurs in the liver and is mainly dependent on intracellular cholesterol concentration. Increasing free cholesterol concentration leads to a reduced LDL-r expression through a mechanism involving transcriptional factors. Counteracting with this process is expected to up- 5 regulate LDL-r expression in the liver and to increase the clearance of LDL cholesterol.
  • SCAP SREBP-cleavage activating protein
  • Two 0 compounds are disclosed, namely 4-(4-chloro-benzoylamino)-N- ⁇ 4-[4-(2-ethoxy-4- ethyl-phenyl)-piperidin-1 -yl]-butyl ⁇ -benzamide and 4-(4-benzoyl)-N- ⁇ 4-[4-(4-isopropyl- 2-methoxy-phenyl)-pipehdin-1-yl]-butyl ⁇ -benzamide hydrochloride, which do not form part of the present invention.
  • R 1 may be hydrogen
  • R 2 may be hydrogen
  • R 3 may be a group
  • X may be an aryl group and n may be 1.
  • group COR 3 is formed from 2- and 4- biphenyl carboxylic acid and R 1 and R 2 are methyl or hydrogen respectively.
  • the utility of the compounds is as opioid receptor binding agents which may be useful as analgesics.
  • the substitution on the 3- and 4- positions of the piperidine ring leave the compounds of this publication outside the scope of the present invention. Furthermore, the utility disclosed is different.
  • the compounds are described as 5HT-1A agonists having CNS activity and may be used as anti-depressants, anti-hypertensive, analgesics etc. It will be noted that the examples of the present invention differ from those of formula (E) in use of a piperidine ring rather than a piperazine and in the utility disclosed.
  • A may represent a substituted phenyl group
  • W represents a linear or branched alkylene group having from 2 to 6 carbon atoms
  • Y may represent a group NHCO or CONH
  • R may be a substituted phenyl group.
  • A may represent a substituted phenyl group
  • W represents a linear or branched alkylene group having from 2 to 6 carbon atoms
  • Y may represent a group NHCO or CONH
  • R may be a substituted phenyl group.
  • R 1 -R 5 are each individually selected from the group of substituents including hydrogen, halogen, hydroxyl, thiol, lower alkyl, substituted lower alkyl, alkenyl, alkynyl, alkylalkenyl, alkylalkynyl, alkoxy, alkylthio, acyl, aryloxy, amino, amido, carboxyl, aryl, substituted aryl, heterocycle, heteroaryl, substituted heterocycle, heteroalkyl, cycloalkyl, substituted cycloalkyl, alkylcycloalkyl, alkylcycloheteroalkyl, nitro and cyano.
  • substituents including hydrogen, halogen, hydroxyl, thiol, lower alkyl, substituted lower alkyl, alkenyl, alkynyl, alkylalkenyl, alkylalkynyl, alkoxy, alkylthio, acyl, aryloxy, amino,
  • the present invention provides aryl piperidine derivatives which are particularly useful in treating cardiovascular disorders associated with elevated levels of circulating LDL-cholesterol.
  • the invention provides a compound of formula (I), physiologically acceptable prodrugs, salts or solvates thereof;
  • radicals contain a total of from 1-4 ring heteroatoms independently selected from oxygen, nitrogen and sulfur, and wherein individual rings of said radicals may be independently saturated, partially unsaturated or aromatic, provided that at least one ring is aromatic;
  • Ar is independently substituted by at least one R 1 group and independently substituted by 0-3 R 3 groups;
  • Ar 2 is a phenyl group, a 5-6 membered heteroaromatic group or a bicyclic heteroaromatic group, where each group is optionally substituted by one or two substituents independently selected from the list: C h alky!, halogen, hydroxy, C 1-4 alkoxy, C 1-6 acyl, C 1-6 acyloxy, amino, C ⁇ alkylamino, di-C ⁇ alkylamino, -(CH 2 ) n NR x R y , -O(CH 2 ) n C(O)NR x R y , -O(CH 2 ) n
  • E is -C ⁇ _ 6 alkylene-
  • X is -CONR 2 -or-NR 2 CO- (where the left hand side of the linkage is attached to E);
  • R 1 is selected from the group consisting of: -O(CR a R°) n C(O)NR x R y , -O(CH 2 ) n CN, -O(CH 2 ) n O(CH 2 ) m OR 2 , -O(CH 2 ) n CO 2 R 2 , -OSO 2 NR x R y , -OSO 2 (CH 2 ) p CH 3 ,
  • R 2 is or hydrogen
  • R 3 is selected from halogen, -O-(C ⁇ -4alkylene)-R 4 or -(C lJt alkylene)-R 4 , where each alkylene group may additionally incorporate an oxygen in the chain, with the proviso that there are at least two carbon atoms between any chain oxygen atoms
  • R 4 is: (i) hydrogen
  • phenyl phenyl fused by a C 3 -8cycloalkyl, naphthyl or a 5- or 6-membered heteroaromatic group, each of which may be optionally substituted by one or two groups independently selected from halogen, C 1-4 alkyl, hydroxy, C 1-4 alkoxy, amino, C 1-4 alkylamino and di-C M alkylamino; (iii) C 3 .
  • R a and R b are independently hydrogen, C 1-4 alkyl or cycloalkyl, where R a and R b are not both cycloalkyl;
  • R x and R y are independently hydrogen, C 1- alkyl, hydroxy or C 1-4 alkoxy, where R x and R y are not both hydroxy or both C 1-4 alkoxy; or R x and R y together with the nitrogen to which they are attached form a 5-membered ring which ring is optionally substituted by -O(CR a R b ) n C(O)NR x R y , -O(CH 2 ) n CN, -O(CH 2 ) n O(CH 2 ) m OR 2 , -O(CH 2 ) n CO 2 R 2 , -OSO 2 NR x R y , -OSO 2 (CH 2 ) p CH 3 ,
  • alkyl, alkylene and alkoxy include both straight and branched chain saturated hydrocarbon groups.
  • alkyl groups include methyl and ethyl groups
  • examples of alkylene groups include methylene and ethylene groups
  • examples of alkoxy groups include methoxy and ethoxy groups.
  • alkenyl includes both straight and branched chain saturated hydrocarbon groups containing one double bond.
  • alkenyl groups include ethenyl or n-propenyl groups.
  • acyl refers to aliphatic or cyclic hydrocarbons attached to a carbonyl group through which the substituent bonds, such as acetyl.
  • phenyl fused by a C 3 . 8 cycloalkyl includes bicyclic rings such as 1,2,3,4-tetrahydronaphthyl, which, for the avoidance of doubt, is linked to the rest of the molecule through the aromatic ring.
  • a halogen atom includes fluorine, chlorine, bromine or iodine.
  • C ⁇ . 3 perfluoroalkyl and C ⁇ perfluoroalkoxy includes compounds in which the hydrogens have been partially or fully replaced by fluorines, such as trifluoromethyl and trifluoromethoxy or trifluoroethyl.
  • a 5-6 membered heteroaromatic group includes a single aromatic ring system containing at least one ring heteroatom independently selected from O, N and S.
  • a 3-7 membered heterocyclyl group means any single ring system containing at least one ring heteroatom independently selected from O, N and S, wherein said ring is saturated, unsaturated or aromatic.
  • An is phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, indolyl, benzofuranyl, benzothiophenyl or indazolyl. More preferably Ar, is phenyl, 1 ,2,3,4- tetrahydronaphthyl or indolyl.
  • the link to the piperidine ring is preferably through the 2- position of he 1,2,3,4-tetrahydronaphthyl moiety and mono- substitution by R 1 is in the corresponding 1- position.
  • the link to the piperidine ring is preferably through the 3-position of the indolyl moiety and mono-substitution by R 1 is in the corresponding 1 -position.
  • E is n-butylene
  • X is -NR 2 CO-.
  • R 2 is hydrogen.
  • Ar 2 is phenyl or a 5-6-membered heteroaromatic group (more preferably phenyl, pyridyl, thiazolyl, oxazolyl or imidazolyl).
  • Ar 3 is phenyl, pyridyl or thienyl, more preferably phenyl.
  • Ar 3 is substituted by halogen (e.g. chloro), (e.g. trifluoromethyl), nitrile, C 1-4 acyl (e.g. acetyl), C 1-4 alkylsulfonyl (e.g. methylsulfonyl) or C 1-4 alkylsulfonylamino.
  • R 1 is selected from the group consisting of: -O(CR a R b ) n C(O)NR x R y , -O(CH 2 ) n CN, -O(CH 2 ) n O(CH 2 ) m OR 2 , -O(CH 2 ) n CO 2 R 2 , -OSO 2 NR x R y , -OSO 2 (CH 2 ) p CH 3 , -(CR a R b ) n C(O)NR x R y and C 2-5 alkenyl; wherein R 2 is C ⁇ alkyl or hydrogen; R a and R are independently hydrogen or C 1-4 alkyl or cycloalkyl; R x and R y are independently hydrogen or C 1-4 alkyl; or R x and R y together with the nitrogen to which they are attached form a 5-member
  • R 3 is not substituted by R 3 , however when An is substituted by R 3 preferred substituents are C ⁇ alkyl or C 1- alkoxy.
  • Ar 2 is optionally substituted by C 1-4 alkyl, halogen, hydroxy or C ⁇ alkoxy. More preferably Ar 2 is not substituted.
  • Particularly preferred compounds of the invention include those in which each variable in Formula (I) is selected from the preferred groups for each variable. Even more preferable compounds of the invention include those where each variable in Formula (I) is selected from the more preferred or most preferred groups for each variable.
  • A is phenyl, naphthyl, 1 ,2,3,4-tetrahydronaphthyl, indolyl, benzofuranyl, benzthiophenyl or indazolyl; where An is independently substituted by at least one R 1 group and independently substituted by 0-3 R 3 groups;
  • Ar 2 is phenyl or a 5-6-membered heteroaromatic group, either of which is optionally substituted by one or two substituents independently selected from the list: C 1-4 alkyl, halogen, hydroxy and C 1-4 alkoxy;
  • Ar 3 is phenyl, pyridyl or thienyl, each of which may be substituted by 1-3 groups independently selected from the group consisting of: halogen (e.g.
  • R 1 is selected from the group consisting of: -O(CR a R b ) n C(O)NR x R y , -O(CH 2 ) n CN,
  • R a and R are independently hydrogen, C 1-4 alkyl or cycloalkyl
  • R x and R y are independently hydrogen or C 1-4 alkyl; or R x and R y together with the nitrogen to which they are attached form a 5-membered ring which ring is optionally substituted by -O(CR a R b ) n C(O)NR x R y , -O(CH 2 ) n CN, -O(CH 2 ) n O(CH 2 ) m OR 2 , -O(CH 2 ) n CO 2 R 2 , -OSO 2 NR x R y , -OSO 2 (CH 2 ) p CH 3 ,
  • n and m are independently 1-3; p is 0-2;
  • R 3 is C ⁇ alkyl or C 1-4 alkoxy.
  • Preferred compounds of formula (I) are selected from the list: 4'-Cyano-biphenyl-4-carboxylic acid ⁇ 4-[4-(1 -carbamoylmethoxy-5,6,7,8-tetrahydro- naphthalen-2-yl)-piperidin-1-yl]-butyl ⁇ -amide (Example 10); 4'-Chloro-biphenyl-4-carboxylic acid ⁇ 4-[4-(1 -carbamoylmethoxy-5,6,7,8-tetrahydro- naphthalen-2-yl)-piperidin-1-yl]-butyl ⁇ -amide (Example 13);
  • substituted means substituted by one or more defined groups.
  • groups may be selected from a number of alternative groups, the selected groups may be the same or different.
  • the term independently means that where more than one substituent is selected from a number of possible substituents, those substituents may be the same or different.
  • physiologically acceptable means a compound which is suitable for pharmaceutical use.
  • Suitable physiologically acceptable salts of the compounds of general formula (I) include acid addition salts formed with pharmaceutically acceptable inorganic acids for example, phosphates, hydrochlorides, hydrobromides or sulphates, or with pharmaceutically acceptable organic acids for example mesylates, lactates and acetates. More suitably, a physiologically acceptable salt of the compounds of general formula (I) is a phosphate salt.
  • the solvates may, for example, be hydrates.
  • prodrugs are also included within the context of this invention.
  • Prodrugs are any covalently bonded carriers that release a compound of structure (I) in vivo when such prodrug is administered to a patient.
  • Prodrugs are generally prepared by modifying functional groups in a way such that the modification is cleaved, either by routine manipulation or in vivo, yielding the parent compound.
  • Prodrugs include, for example, compounds of this invention wherein hydroxy, amine or sulfhydryl groups are bonded to any group that, when administered to a patient, cleaves to form the hydroxy, amine or sulfhydryl groups.
  • prodrugs include (but are not limited to) acetate, formate and benzoate derivatives of alcohol, sulfhydryl and amine functional groups of the compounds of formula (I).
  • esters may be employed, such as methyl esters, ethyl esters, and the like.
  • compounds, their pharmaceutically acceptable salts, their solvates and polymorphs, defined in any aspect of the invention are referred to as "compounds of the invention”.
  • Compounds of the invention may be administered as the raw chemical but the active ingredient is preferably presented as a pharmaceutical formulation.
  • Compounds of the invention may be formulated for oral, buccal, parenteral, transdermal, topical (including ophthalmic and nasal), depot or rectal administration or in a form suitable for administration by inhalation or insufflation (either through the mouth or nose).
  • the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium starch glycollate); or wetting agents (e.g. sodium lauryl sulphate).
  • binding agents e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose
  • fillers e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate
  • lubricants e.g. magnesium stearate, talc or silica
  • disintegrants e.g. potato starch or sodium starch glycollate
  • Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use.
  • Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g. sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g. lecithin or acacia); non-aqueous vehicles (e.g. almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g. methyl or propyl-p- hydroxybenzoates or sorbic acid).
  • the preparations may also contain buffer salts, flavouring, colouring and sweetening agents as appropriate.
  • Preparations for oral administration may be suitably formulated to give controlled release of the active compound.
  • compositions may take the form of tablets or lozenges formulated in conventional manner.
  • compounds of the invention may be formulated as creams, gels, ointments or lotions or as a transdermal patch.
  • Such compositions may for example be formulated with an aqueous or oily base with the addition of suitable thickening, gelling, emulsifying, stabilising, dispersing, suspending, and/or colouring agents.
  • the compounds of the invention may be formulated for parenteral administration by bolus injection or continuous infusion.
  • Formulations for injection may be presented in unit dosage form e.g. in ampoules or in multi-dose containers, with an added preservative.
  • the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents.
  • the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen- free water, before use.
  • the compounds of the invention may be formulated for topical administration in the form of ointments, creams, gels, lotions, pessaries, aerosols or drops (e.g. eye, ear or nose drops).
  • Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents.
  • Ointments for administration to the eye may be manufactured in a sterile manner using sterilised components.
  • Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents, thickening agents, or colouring agents. Drops may be formulated with an aqueous or non aqueous base also comprising one or more dispersing agents, stabilising agents, solubilising agents or suspending agents. They may also contain a preservative.
  • the compounds of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, e.g. containing conventional suppository bases such as cocoa butter or other glycerides.
  • the compounds of the invention may also be formulated as depot preparations. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
  • the compounds of the invention may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
  • the compounds of the invention may be formulated as solutions for administration via a suitable metered or unit dose device or alternatively as a powder mix with a suitable carrier for administration using a suitable delivery device.
  • compositions may contain from 0.1% upwards, e.g. 0.1 - 99% of the active material, depending on the method of administration.
  • a proposed dose of the compounds of the invention is 0.25mg/kg to about 125mg/kg bodyweight per day e.g. 20mg/kg to 100mg/kg per day. It will be appreciated that it may be necessary to make routine variations to the dosage, depending on the age and condition of the patient and the precise dosage will be ultimately at the discretion of the attendant physician or veterinarian. The dosage will also depend on the route of administration and the particular compound selected.
  • the compounds of the invention may, if desired, be administered with one or more therapeutic agents and formulated for administration by any convenient route in a conventional manner. Appropriate doses will be readily appreciated by those skilled in the art.
  • the compounds of the invention may be administered in combination with an HMG CoA reductase inhibitor, an agent for inhibition of bile acid transport or fibrates.
  • the compounds of the invention are inducers of LDL-r expression and are thus of use in the treatment of conditions resulting from elevated circulating levels of LDL- cholesterol.
  • compounds of the invention are of use in the treatment of diseases in which lipid imbalance is important, e.g. atherosclerosis, pancreatitis, non-insulin dependent diabetes mellitus (NIDDM), coronary heart diseases and obesity.
  • NIDDM non-insulin dependent diabetes mellitus
  • compounds of the invention are also useful in lowering serum lipid levels, cholesterol and/or triglycerides, and are of use in the treatment of hyperlipemia, hyperlipidemia, hyperlipoproteinemia, hypercholesterolemia and/or hypertriglyceridemia. It will be appreciated that reference to treatment is intended to include prophylaxis as well as the alleviation of established symptoms.
  • Compounds of formula (lb), i.e. compounds of formula (I) where R 1 is -OR, may be prepared from the corresponding hydroxy compound (IV) according to reaction scheme 2.
  • Preferred reaction conditions comprise treating (IV) with a suitable base such as sodium hydride or caesium carbonate followed by addition of RL where L is a leaving group such as halogen.
  • Compounds of formula (IV) may be prepared by adapting methods described herein for the preparation of compounds of formula (I).
  • Compounds of formula (I) where An is a nitrogen containing heterocycle may be substituted on the nitrogen by nucleophilic substitution.
  • substitution may be effected by treating (I) with base such as sodium hydride followed by reaction with a suitable nucleophile.
  • Compounds of formula (I) may be prepared be coupling boronic acid compounds of formula (V) with compounds of formula (VI) according to reaction scheme 3.
  • Preferred reaction conditions comprise treatment with Pd(PPh 3 ) 4 and a suitable base such as sodium carbonate at elevated temperature.
  • Compounds of formula (II) may be prepared according to reaction scheme 4 by reacting a compound of formula (VII) with a compound of formula (VIII) where L is a leaving group such as halogen and P is a suitable protecting group.
  • Preferred conditions comprise reaction with a suitable base such as potassium carbonate. Removal of protecting group P gives compounds of formula (II).
  • a preferred nitrogen protecting group is where the nitrogen attached to E and group R 2 form phthalimide (i.e. 1 ,3-dioxo-1 ,3-dihydro-isoindol-2-yl). Removal of the phthalimide protecting group gives compounds of formula (II) where R 2 is hydrogen.
  • Preferred conditions comprise treatment with hydrazine at elevated temperature.
  • Compounds of formula (VII) may be prepared by methods described in the experimental section hereinbelow.
  • Compounds of formula (VIII) are either known or may be prepared from known compounds by methods available to the skilled person.
  • the protecting groups used in the preparation of compounds of formula (I) may be used in conventional manner. See for example 'Protective Groups in Organic Chemistry' Ed. J. F. W. McOmie (Plenum Press 1973) or 'Protective Groups in Organic Synthesis' by Theodora W Greene and P M G Wuts (John Wiley and Sons 1991).
  • Conventional amino protecting groups may include for example aralkyl groups, such as benzyl, diphenylmethyl or triphenylmethyl groups; and acyl groups such as N-benzyloxycarbonyl or t-butoxycarbo ⁇ yl.
  • Conventional carboxylic acid protecting groups include methyl and ethyl groups.
  • composition comprising a compound of the invention and a pharmaceutically acceptable carrier or diluent
  • a compound of the invention in the manufacture of a medicament for the treatment or prophylaxis of a disorder in which lipid imbalance is important such as atherosclerosis, pancreatitis, non-insulin dependent diabetes mellitus (NIDDM), coronary heart diseases and obesity);
  • NIDDM non-insulin dependent diabetes mellitus
  • a compound of the invention in the manufacture of a medicament for the treatment or prophylaxis of hyperlipemia, hyperlipidemia, hyperlipoproteinemia, hypercholesterolemia and/or hypertriglyceridemia;
  • vii) a method of treatment or prophylaxis of a disorder resulting from elevated circulating levels of LDL-cholesterol in a human patient comprising administering to the human an effective amount of a compound of the invention;
  • viii) a method of lowering serum lipid levels, cholesterol and/or triglycerides in a human patient comprising administering to the human an effective amount of a compound of the invention; and ix) a combination of a compound of the invention with an HMG CoA reductase inhibitor, an agent for inhibition of bile acid transport or a fibrate.
  • the invention provides a compound of formula (I)
  • radicals contain a total of from 1-4 ring heteroatoms independently selected from oxygen, nitrogen and sulfur, and wherein individual rings of said radicals may be independently saturated, partially unsaturated, or aromatic, provided that at least one ring is aromatic, where An bears at least one group independently represented by R 1 and 0-3 groups independently represented by R 3 ;
  • R 1 is selected from the group consisting of: -O(CH 2 ) n C(O)NR x R y , -O(CH 2 ) n CN, -O(CH 2 ) n O(CH 2 ) m OR 2 , CLsalkenyl, -O(CH 2 ) n C(O)OR 2 , and -OSO 2 (CH 2 ) p CH 3 ;
  • R 2 is (CH 2 ) n CH 3 or H;
  • R x and R y are independently C 1- alkyl or H; n and m are independently 1 -4; p represents 0-4;
  • R 3 is selected from halogen, - ⁇ -(Co--! alkylene)-R 4 or -(C 0 ⁇ alkylene)-R 4 , where each alkylene group may additionally incorporate an oxygen in the chain, with the proviso that there are at least two carbon atoms between any chain heteroatoms; R 4 represents
  • heterocyclyl selected from the group consisting of monocyclic radicals and fused polycyclic radicals, wherein said radicals contain a total of from 5-14 ring atoms, wherein said radicals contain a total of from 1-4 ring heteroatoms independently selected from oxygen, nitrogen and sulfur, and wherein individual rings of said radicals may be independently saturated, partially unsaturated, or aromatic, providing that at least one ring is aromatic, where Ar 3 is optionally substituted by 1 -4 groups independently selected from the group consisting of: hydroxy, alkyl, C M alkoxy, C 2 .
  • X represents -CON(H or C ⁇ alkyl )-or -N(H or C alkyl)CO-; or a physiologically acceptable prodrug, salt or solvate thereof.
  • Example 1 4'-Trifluoromethyl-biphenyl-4-carboxylic acid (4-f4-(1-carbamoylmethoxy- 5,6.7,8-tetrahvdro-naphthalen-2-yl)-piperidin-1-yll-butyl>-amide
  • Example 3 4'-Trifluoromethyl-biphenyl-4-carboxylic acid [4-(4-f1-f2-(2-methoxy- ethoxy)-ethoxyl-5,6,7,8-tetrahvdro-naphthalen-2-yl>-piperidin-1-yll-butyl ⁇ -amide
  • Example 4 4'-Trifluoromethyl-biphenyl-4-carboxylic acid f4-(4-(1-[2-(2-hydroxy- ethoxy)-ethoxy1-5,6,7,8-tetrahvdro-naphthalen-2-yl)-piperidin-1-yll-butyl)-amide
  • Example 7 4'-Cyano-biphenyl-4-carboxylic acid (4-(4-f5-methoxy-1-(2-methyl-allyl)- 1 H-indol-3-yll-piperidin-1 -yl)-butyl)-amide;
  • Example 8 f2-(H4-f(4'-Trifluoromethyl-biphenyl-4-carbonyl)-aminol-butyl)-piperidin- 4-yl)-5,6,7,8-tetrahvdro-naphthalen-1-yloxy1-acetic acid ethyl ester
  • example 8 To a solution of example 8 (0.3 g, 0.47 mmol) in EtOH was added a 1 N NaOH solution (0.5 mL, 1.1 eq) and the mixture was stirred at reflux overnight. The resulting mixture was acidified with a 1N HCI solution (2.2 eq) and evaporated. Crystallisation from H 2 O/DCM/iPr 2 O (50/2/48) gave the title compound as white crystals (0.18 g, 0.3 mmol) in a 60% yield; m.p. 100°C (become gummy solid); LC/Tof : ES + 609.2920 3.3ppm.
  • Example 10 4'-Cvano-biphenyl-4-carboxylic acid ⁇ 4-r4-(1-carbamoylmethoxy-5, 6,7,8- tetrahydro-naphthalen-2-yl)-piperidin-1-yll-butyl)-amide
  • Example 11 4'-Trifluoromethyl-biphenyl-4-carboxylic acid (4-f4-(4- carbamoylmethoxy-2,5-dimethyl-phenyl)-piperidin-1-yll-butyl)-amide
  • Example 12 Methanesulfonic acid 2,5-dimethyl-4-(1- ⁇ 4-f(4'-trifluoromethyl-biphenyl- 4-carbonyl)-aminol-butyl ⁇ -piperidin-4-yl)-phenyl ester
  • Example 13 4'-Chloro-biphenyl-4-carboxylic acid (4-r4-(1-carbamoylmethoxy- 5,6,7,8-tetrahydro-naphthalen-2-yl)-piperidin-1-vn-butyl)-amide
  • Example 14 2',4'-Dichloro-biphenyl-4-carboxylic acid H- -d-carbamoylmethoxy- 5,6.7.8-tetrahvdro-naphtalen-2-yl)-piperidin-1-vH-butyl)-amide
  • Example 15 4'-Cvano-biphenyl-4-carboxylic acid (4-r4-(1-methylcarbamoylmethoxy- 5.6,7.8-tetrahvdro-naphthalen-2-yl)-piperidin-1-vn-butyll-amide
  • Example 17 2-(4-Cvano-phenyl)-4-methyl-thiazole-5-carboxylic acid (4-f4-(1- carbamoylmetho ⁇ y-5,6,7,8-tetrahydro-naphthalen-2-yl)-piperidin-1-v ⁇ -butyl>-amide
  • Example 18 2-(4-Cvano-phenyl)-4-methyl-oxazole-5-carboxylic acid (4-f4-(1- carbamoylmethoxy-5,6,7,8-tetrahvdro-naphthalen-2-yl)-piperidin-1-yll-butyl>- amide
  • Example 19 Sulfamic acid 2-(1-(4-[(4'-cyano-biphenyl-4-carbonyl)-aminol-butyl)- piperidin-4-yl)-5,6,7,8-tetrahydro-naphthalen-1 -yl ester
  • Example 20 4'-Methanesulfonylamino-biphenyl-4-carboxylic acid (4-14-d- carbamoylmethoxy-5,6.7.8-tetrahvdro-naphthalen-2-yl)-piperidin-1-vn-butyl)-amide
  • Example 21 4'-Chloro-2-hvdroxy-biphenyl-4-carboxylic acid 4-f4-(1- carbamoylmethoxy-5,6,7,8-tetrahvdro-naphthalen-2-yl)-piperidin-1-yll-butyl)-amide
  • Example 22 4-(5-Acetyl-thiophen-2-yl)- ⁇ -(4-r4-(1-carbamoylmethoxy-5,6,7,8- tetrahydro-naphthalen-2-yl)-piperidin-1-yll-butyl)-benzamide
  • Example 23 4'-Cvano-biphenyl-4-carboxylic acid (4-14-11 -(2-methyl-allyl)-1 /-/-indazol- 3-yll-piperidin-1-yl)-butyl)-amide
  • Example 25 4'-Cvano-biphenyl-4-carboxylic acid (4- 4-f1-(1-carbamoyl-ethoxy)- 5,6,7,8-tetrahydro-naphthalen-2-yll-piperidin-1-yl ⁇ -butyl)-amide
  • Example 26 ⁇ /-(4-f4-(1 -Carbamoylmethoxy-5,6,7,8-tetrahvdro-naphthalen-2-yl)- piperidin-1-yll-butyl ⁇ -6-(4-chloro-phenyl)-nicotinamide
  • Example 28 4'-Cvano-biphenyl-4-carboxylic acid (4-(4-f1-(1-carbamoyl-1-methyl- ethoxy)-5,6,7,8-tetrahvdro-naphthalen-2-yll-piperidin-1-ylVbutyl)-amide
  • Example 29 4'-Chloro-biphenyl-4-carboxylic acid (4-(4-f1-(1-carbamoyl-1-methyl- ethoxy)-5,6,7,8-tetrahvdro-naphthalen-2-yll-piperidin-1-ylVbutyl)-amide
  • Example 31 ⁇ /-(4-f4-(1-Carbamoylmethoxy-5,6,7,8-tetrahvdro-naphthalen-2-yl)- piperidin-1-yll-butyl)-4-(5-cvano-pyridin-2-yl)-benzamide
  • Example 32 ⁇ /- ⁇ 4-r4-(1-Carbamoylmethoxy-5,6,7,8-tetrahvdro-naphthalen-2-yl)- piperidin-1-yll-butyl ⁇ -4-(5-chloro-pyridin-2-yl)-benzamide
  • Example 35 /V- 4-r4-(1-Carbamoylmethoxy-5,6,7,8-tetrahvdro-naphthalen-2-yl)- piperidin-1-yH-butylV6-(4-cvano-phenyl)-nicotinamide
  • Example 37 f2-(1-(4-r(4'-Cyano-biphenyl-4-carbonyl)-amino1-butyl)-piperidin-4-yl)- 5,6, 7, 8-tetrahydro-naphthalen-1 -yloxyl-acetic acid
  • HepG 2 cells stably transfected with a construct comprising the LDL-r promoter and the luciferase reporter gene, were seeded at 50.000 cells/well in 96 well plates. After 1 day, cells were incubated with compounds for 24 hours in RPMI medium containing 2% of lipoprotein-deficient serum. Compounds were tested from 10 "6 M to 10 "9 M. Cell lysates were prepared and the luciferase activity was measured by the luciferase assay system (Promega). Induction of luciferase activity was calculated taking untreated cells as control. The ED 5 o ⁇ f each compounds was determined compared to the ED 50 of an internal standard.
  • the compounds of the invention are potent and specific inducers of LDL-r expression.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

L'invention concerne de nouveaux composés augmentant la régulation de l'expression des récepteurs des LDL (LDL-r), leurs procédés de préparation, ainsi que des compositions pharmaceutiques contenant lesdits composés et leur utilisation médicale. L'invention concerne, plus particulièrement de nouvelles pipéridines aromatiques représentées par la formule (I) et leur utilisation en thérapie. Dans cette formule, Ar1 est substitué par au moins un groupe R1 sélectionné dans le groupe constitué par: -O(CRaRb)nC(O)NRXRy, -O(CH2)nCN, -O(CH2)nO(CH2)mOR2, -O(CH2)nCO2R2, -OSO2NRxRy, -OSO2(CH2)pCH3, -(CRaRb)nC(O)NRXRy, -(CH2)nCN, -(CH2)nO(CH2)mOR2, -(CH2)nCO2R2, -(CH2)nC(O)R2, - SO2NRxRy, -SO2(CH2)pCH3, -CH=CHC(O)NRxRy, -CH=CHCN, -CH=CHCO2R2, -CO2R2, - C(O)R2, -C(O)NRxRy et C2-5alcényle.
PCT/EP2003/007613 2002-07-12 2003-07-11 Derives d'aryl piperidine utilises comme inducteurs d'expression des recepteurs des lipoproteines de basse densite (ldl) permettant de traiter l'hypercholesterolemie WO2004006923A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003250058A AU2003250058A1 (en) 2002-07-12 2003-07-11 Aryl piperidine derivatives as inducers of ldl-receptor expression for the treatment of hypercholesterolemia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0216252.7 2002-07-12
GBGB0216252.7A GB0216252D0 (en) 2002-07-12 2002-07-12 Compounds

Publications (1)

Publication Number Publication Date
WO2004006923A1 true WO2004006923A1 (fr) 2004-01-22

Family

ID=9940363

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/007613 WO2004006923A1 (fr) 2002-07-12 2003-07-11 Derives d'aryl piperidine utilises comme inducteurs d'expression des recepteurs des lipoproteines de basse densite (ldl) permettant de traiter l'hypercholesterolemie

Country Status (5)

Country Link
AR (1) AR040541A1 (fr)
AU (1) AU2003250058A1 (fr)
GB (1) GB0216252D0 (fr)
TW (1) TW200412953A (fr)
WO (1) WO2004006923A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858666B2 (en) 2007-06-08 2010-12-28 Mannkind Corporation IRE-1α inhibitors
CN115477607A (zh) * 2022-10-14 2022-12-16 泰兴市锐容新材料科技合伙企业(有限合伙) 一种光稳定剂中间体及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001006261A2 (fr) * 1999-07-17 2001-01-25 Glaxo Group Limited Competition de liaison d'antagonistes de la proteine d'activation de clivage de srebp (scap)
WO2002055495A1 (fr) * 2001-01-15 2002-07-18 Glaxo Group Limited Derives aryle de piperidine comme inducteurs de l'expression du recepteur ldl
WO2002055497A1 (fr) * 2001-01-15 2002-07-18 Glaxo Group Limited Derives d'arylepiperidine utilises comme inducteurs d'expression de ldl
WO2002055496A1 (fr) * 2001-01-15 2002-07-18 Glaxo Group Limited Derives aryle de piperidine et de piperazine comme inducteurs de l'expression du recepteur ldl

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001006261A2 (fr) * 1999-07-17 2001-01-25 Glaxo Group Limited Competition de liaison d'antagonistes de la proteine d'activation de clivage de srebp (scap)
WO2002055495A1 (fr) * 2001-01-15 2002-07-18 Glaxo Group Limited Derives aryle de piperidine comme inducteurs de l'expression du recepteur ldl
WO2002055497A1 (fr) * 2001-01-15 2002-07-18 Glaxo Group Limited Derives d'arylepiperidine utilises comme inducteurs d'expression de ldl
WO2002055496A1 (fr) * 2001-01-15 2002-07-18 Glaxo Group Limited Derives aryle de piperidine et de piperazine comme inducteurs de l'expression du recepteur ldl

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858666B2 (en) 2007-06-08 2010-12-28 Mannkind Corporation IRE-1α inhibitors
US8614253B2 (en) 2007-06-08 2013-12-24 Mannkind Corporation IRE-1α inhibitors
US9241942B2 (en) 2007-06-08 2016-01-26 Mannkind Corporation IRE-1α inhibitors
US9546149B2 (en) 2007-06-08 2017-01-17 Mannkind Corporation IRE-1α inhibitors
US9981901B2 (en) 2007-06-08 2018-05-29 Fosun Orinove Pharmatech, Inc. IRE-1α inhibitors
CN115477607A (zh) * 2022-10-14 2022-12-16 泰兴市锐容新材料科技合伙企业(有限合伙) 一种光稳定剂中间体及其制备方法
CN115477607B (zh) * 2022-10-14 2024-05-24 肖尖 一种光稳定剂中间体及其制备方法

Also Published As

Publication number Publication date
AR040541A1 (es) 2005-04-13
TW200412953A (en) 2004-08-01
GB0216252D0 (en) 2002-08-21
AU2003250058A1 (en) 2004-02-02

Similar Documents

Publication Publication Date Title
US6130235A (en) Compounds and methods to treat cardiac failure and other disorders
JP4322113B2 (ja) 新規カルボン酸アミド化合物
US20040077654A1 (en) Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
US20040006081A1 (en) Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity
US20040102432A1 (en) Chemical compounds
WO1999061426A1 (fr) Composes heterocycliques et methodes de traitement de l'insuffisance cardiaque et autres troubles
JP2004507461A (ja) 新規化合物
JP2010520876A (ja) ピペラジンおよびピペリジンｍＧｌｕＲ５増強剤
NO311213B1 (no) Kinolinkarboksamid-derivater, deres fremstilling og deres anvendelse som Neurokinin 3 (NK-3)- og Neurokinin 2 (NK-2)reseptorantagonister, samt farmasöytiske preparater inneholdendedem
EP1135378A1 (fr) Derives benzamidiques et leur utilisation comme inhibiteurs de la secretion d'apob-100
US6566376B1 (en) Diphenyl-piperidine derivative
KR20040084920A (ko) 화합물
NO340489B1 (no) Nye benzylpiperazinderivater, fremgangsmåter for deres fremstilling og anvendelse ved behandling av gastrointestinale forstyrrelser
JP2013151536A (ja) 脊髄性筋萎縮症のための２，４−ジアミノキナゾリン
EP1660481A1 (fr) Derives carboxamides de piperidine/cyclohexane destines a etre utilises comme modulateurs du recepteur vanilloide
US6395753B1 (en) Cyclic amine compounds and pharmaceutical composition containing the same
WO2004006922A1 (fr) Derives de piperidine-aryle servant d'inducteurs de l'expression du recepteur ldl pour le traitement de l'hypercholesterolemie
EP1771429A1 (fr) Nouveaux derives d'uree benzoyle
JP2008501687A (ja) ヒスタミンｈ３受容体薬剤、調製、及び治療的使用
US20040072865A1 (en) Aryl piperidine derivatives as inducers of ldl-receptor expression
WO2004006923A1 (fr) Derives d'aryl piperidine utilises comme inducteurs d'expression des recepteurs des lipoproteines de basse densite (ldl) permettant de traiter l'hypercholesterolemie
JP2004520348A (ja) Ｌｄｌ−受容体発現のインデューサーとしてのアリールピペリジン誘導体
EP1534280A1 (fr) Derives d'aryle piperidine et utilisation de ceux-ci pour reduire des taux eleves de ldl-cholesterol
US4518713A (en) Analgesic substituted-1-aminoalkylamino-4-aryloxypiperidines
JP2005501866A (ja) ケモカイン受容体活性のモジュレーターとしての新規ピペリジニル誘導体

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP